Fagron NV, a pharmaceutical compounding company, provides personalized medicine care to hospitals, pharmacies, clinics, and patients. The company also innovates concepts, vehicles, and formulations for pharmaceutical compounding. In addition, it supplies raw materials, utensils and equipment, semi-finished products, vehicles, and sterile and non-sterile compounded medicines. Further, the company offers education and training program to prescribers and pharmacists through the Fagron Academy. It has operations in Latin America, North America, Europe, the Middle East, and Africa. The company was formerly known as Arseus NV and changed its name to Fagron NV in January 2015. Fagron NV was founded in 1990 and is based in Nazareth, Belgium.

Fagron NV

Baltisse is an investment company focused on value creation through entrepreneurship, supporting entrepreneurs in realizing their growth ambitions.

Baltisse

Lachman Consultants is a regulatory and technical consulting firm providing services to pharmaceutical, medical device, and biologics clients globally since 1978.  The self-described leader offers compliance, regulatory affairs, and science & technology services.

Lachman Consultants

Fagron is involved in the development and production of personalized medicines and pharmaceutical products. Self-described as having a presence in EMEA, North America, and Latin America.

Metric
Company Name	Fagron NV	Baltisse	Lachman Consultants
Symbol	FAGR
MSH ID	COM:FAGRON	COM:BALTISSE	COM:LACHMANCONSULTANTS
Market	STOCKS	PRIVATE	PRIVATE
Sector	Healthcare	Financial Services & Finance	Commercial & Professional Services
Industry	Drug Manufacturers - Specialty & Generic	Investment Management	Consulting
Country	BE	BE	US
Stage
Employee Count	3.28K
Website	fagron.com	baltisse.com	lachmanconsultants.com
LinkedIn
Founders

Metric
Market Cap	1.40B
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue	803.71M
Revenue (LTM)
Revenue (NTM)
Gross Profit	164.38M
EBITDA	147.43M
Operating Income	111.07M
Net Income	74.31M
EPS	1.02
Diluted EPS	1.02
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.33
Operating Profit Margin	0.15
EBITDA Margin	0.18
Net Profit Margin	0.09
Return on Equity	0.17
Return on Assets	0.07
Return on Capital Employed	0.14

COM:FAGRON

Fagron

Last Close

18.62

25/11 09:22

Market Cap

1.34B

Beta: -

Volume Today

4.86K

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	17.78
P/B Ratio	3.07
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	1.86
EV Multiple	8.20

Metric
Days Sales Outstanding
Days Payables Outstanding	89.81
Days Inventory Outstanding	88.07
Operating Cycle	126.59
Cash Conversion Cycle	60.86
Asset Turnover	0.79

Metric
Operating Cash Flow	113.11M
Free Cash Flow	72.58M
Cash Flow to Debt	0.32
Operating Cash Flow/Sales	0.14
Free Cash Flow Yield	0.07

Metric
Cash & Equivalents	140.11M
Accounts Receivable
Inventory	120.02M
Goodwill	457.54M
Debt to Capitalization	0.43
Debt to Assets	0.41
Current Ratio	1.86
Quick Ratio	1.27

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.00
R&D to Revenue
SG&A to Revenue